Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00515879 · ClinicalTrials.gov registry record · Phase 3
Effect of D-cycloserine Plus Cognitive Behavioral Therapy on People With Social Phobia
A Phase 3 study, sponsored by Boston University Charles River Campus.
- Completed
- Registry status
- Phase 3
- Development phase
- 169
- Enrollment target
NCT00515879: Completed Phase 3 study, sponsored by Boston University Charles River Campus.
NCT00515879 is a Phase 3 study that has completed, run by Boston University Charles River Campus. The registered enrollment target is 169 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (78% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00515879, a Phase 3 study, has completed, sponsored by Boston University Charles River Campus.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 169 participants
- Enrollment target
Study Summary
This study will assess the effectiveness of D-cycloserine combined with cognitive-behavior therapy in treating people with social anxiety disorder.
Primary Outcome
Social Phobic Disorders Severity and Change Form (SPD-SC Form; Liebowitz et al., 1992) is an expansion and adaptation of the Clinical Global Impression Scale (CGI) by Guy (1976) to SAD. Similar to the original CGI scale, the SPD-SC Form is rated by an independent evaluator on a 7-point scale to indicate severity (1=normal/not ill; 2 = minimally ill; 3=mildly ill; 4=moderately ill; 5=markedly ill; 6=severely ill; 7=among the most severely ill) and improvement (1=very much improved; 2=much improve
Interventions
- DRUG Placebo
- BEHAVIORAL Cognitive behavioral therapy (CBT)
- DRUG D-cycloserine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 169 participants |
| Start Date | 2007-12 |
| Est. Completion | 2011-12 |
| Phase | Phase 3 |
What the finished NCT00515879 record still lists
NCT00515879 is an interventional study that assigns participants to a tested intervention. The registered 169 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (78% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00515879 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00515879 about?
NCT00515879 is a clinical study titled "Effect of D-cycloserine Plus Cognitive Behavioral Therapy on People With Social Phobia". This study will assess the effectiveness of D-cycloserine combined with cognitive-behavior therapy in treating people with social anxiety disorder.
What is the current status of trial NCT00515879?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 169 participants. The study started on 2007-12. Estimated completion is 2011-12.
What interventions are being tested in trial NCT00515879?
The interventions under investigation include: Placebo (DRUG), Cognitive behavioral therapy (CBT) (BEHAVIORAL), D-cycloserine (DRUG).
Who is sponsoring clinical trial NCT00515879?
This trial is sponsored by Boston University Charles River Campus, which has 104 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00515879's enrollment target sits among peer trials
169 1459th of 2000 higher than 542 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06191484 · 169 participants · NA
Risk and Resilience to Suicide Following Late-Life Spousal Bereavement
- NCT02016430 · 170 participants · NA
Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)
- NCT02621021 · 170 participants · Phase 2
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
- NCT04094701 · 170 participants · NA
Hip Arthroscopy Postoperative Opioid Demands
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia